Efforts are Underway to Tackle Immunotherapy Resistance in Refractory RCC

Video

Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.

During the 2023 Genitourinary Cancers Symposium, CancerNetwork® spoke with Tian Zhang, MD, MHS, regarding efforts to overcome mechanisms of resistance to immune checkpoint inhibitors in patients with recurrent renal cell carcinoma (RCC) beyond the second line of treatment.

According to Zhang, an associate professor in the Department of Medicine at Harold C. Simmons Comprehensive Cancer Center of the University of Texas Southwestern Medical Center, several strategies are being assessed to mitigate immune checkpoint resistance in patients who have received first-line immunotherapy. These include increasing cancer antigen presentation as well as working with tumor cells in or administering novel cells to the microenvironment.

In her presentation at the meeting, Zhang highlighted a phase 1/2 study (NCT03530397) investigating bispecific MEDI5752 as a strategy for overcoming resistance mechanisms in patients with advanced tumors. Investigators reported that MEDI5752 elicited an overall response rate of about 58% in the immunotherapy-naïve population; in the presentation, Zhang noted that more time was needed to determine how the refractory population will respond to treatment.

Transcript:

When we’re thinking about immune checkpoint resistance, there are a lot of great people thinking about this problem because it is quite an important problem in patients who have had first-line immunotherapy options and are developing resistance and disease growth.

Multiple ways to tackle mechanisms of resistance are underway, whether that’s through increasing cancer antigen presentation, working with the cells in the microenvironment, or even delivering novel cells into the tumor microenvironment. There are many early phase studies that are looking at these possibilities to tackle these mechanisms of resistance.

If we’re not curing enough patients in the frontline setting with the currently available or next generation immunotherapy treatments, for example, we will be looking more and more at patients who have refractory disease to frontline therapies.

Developing novel agents and strategies to overcome those mechanisms of resistance are going to be very important. I think there are some exciting targets for bispecific [antibodies] and cellular therapies like CAR T cells, [which] have made a difference in hematologic malignancies. [They] are starting to make their way into solid tumors and, in particular, kidney cancer.

Reference

Albiges L, Rodriguez LM, Kim S, et al. Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): preliminary results from an FTIH trial. J Clin Oncol. 2022;40(16):107-107. Doi:10.1200/JCO.2022.40.16_suppl.107

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Related Content